On December 11, the Medicines Patent Pool announced a new licensing agreement for a 2013 WHO recommended second-line antiretroviral, atazanavir (ATV). At this point, it is important for IP activists, generic companies, and countries to understand both the express territorial coverage of the license (110 countries) and its “effective” territorial coverage as well (144 countries plus the possibility of compulsory licensing expansion). Because royalty payments are actually limited to situations where granted patents are in effect – and with some exceptions even then, it is also important to identify the limited circumstances where royalties will be imposed. Finally, it is important to analyze some of the licensed or patent-free availability or ritonavir or cobicistat for co-formulated boosting.
Follow
Free to Share
Comments on:
- An error has occurred, which probably means the feed is down. Try again later.
Civil Society Documents
- An error has occurred, which probably means the feed is down. Try again later.
Comments on:
- An error has occurred, which probably means the feed is down. Try again later.
industry | infojustice
- Aspen Doesn’t Want You to Own Your Own Casebooks
- Still Profitable After All These Years
- Recording Industry Reports Growth from User-Generated Content and New Projects in Emerging Economies
- EC Trade Negotiators and Industry Discuss How to ‘Re-Educate’ Public About Intellectual Property Rights (talk about employment)
- Witnesses at U.S. Trade Hearing Offer Opinions (and Warnings) on Intellectual Property in Upcoming Negotiations with the EU